Trade Apellis Pharmaceuticals, Inc. - APLS CFD

Add to favourite

33.96

1.39%

0.12

Low: 33.78

High: 35.5

Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

0.12

Long position overnight fee

-0.024262%

Short position overnight fee

0.00204%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	34.44
Open	34.2
1-Year Change	-23.92%
Day's Range	33.78 - 35.5

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 17, 2024	34.44	1.67	5.10%	32.77	34.77	32.77
Dec 16, 2024	33.60	0.85	2.60%	32.75	34.87	32.66
Dec 13, 2024	33.14	0.66	2.03%	32.48	33.41	31.71
Dec 12, 2024	32.68	-0.77	-2.30%	33.45	34.03	32.25
Dec 11, 2024	33.93	-0.67	-1.94%	34.60	34.81	33.92
Dec 10, 2024	34.58	-0.47	-1.34%	35.05	35.19	34.14
Dec 9, 2024	34.95	1.74	5.24%	33.21	35.63	33.21
Dec 6, 2024	33.41	0.11	0.33%	33.30	34.25	32.96
Dec 5, 2024	33.37	-0.49	-1.45%	33.86	34.13	32.62
Dec 4, 2024	34.06	-0.06	-0.18%	34.12	34.65	33.71
Dec 3, 2024	34.58	-0.23	-0.66%	34.81	35.30	33.75
Dec 2, 2024	35.34	1.61	4.77%	33.73	35.46	33.73
Nov 29, 2024	33.83	-0.14	-0.41%	33.97	34.56	33.72
Nov 27, 2024	34.06	1.34	4.10%	32.72	34.31	32.72
Nov 26, 2024	32.55	0.55	1.72%	32.00	32.91	31.64
Nov 25, 2024	31.84	0.82	2.64%	31.02	32.98	31.02
Nov 22, 2024	30.70	3.04	10.99%	27.66	30.93	27.61
Nov 21, 2024	27.67	0.72	2.67%	26.95	28.03	26.56
Nov 20, 2024	27.38	-1.32	-4.60%	28.70	28.88	27.32
Nov 19, 2024	28.89	0.49	1.73%	28.40	30.71	27.70

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Industry:

Biopharmaceuticals

100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US

News

Pi Network coin price prediction: Third party price target

Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com

13:51, 13 December 2024

Euro forecast: third party data roundup

In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.

22:39, 12 December 2024

Projected US interest rates in 5 years: Third party round up

As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?

14:28, 12 December 2024

Street in City of London with Royal Exchange, Bank of England and new modern skyscrapers

Projected UK interest rates in 5 years

Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?

11:20, 12 December 2024